CEO Joshua Silverman Buys 100k Shares in PharmaCyte Amid Downturn: Insider Confidence Amid Volatile Biotech Stock
Insider buying surge at PharmaCyte Biotech shows CEO Silverman buying $0.78‑$0.83 shares despite losses, hinting a hidden value in a volatile biotech stock.
3 minutes to read